Telitacicept, a dual inhibitor of the cytokines B-lymphocyte stimulator and a proliferation-inducing ligand, showed efficacy ...
Objective: To address this gap, we conducted a pre-registered meta-analysis to synthesize findings from rigorously designed randomized controlled trials (i.e., low attrition, comparable baseline ...
This review included randomized controlled trials (RCTs) that studied the effectiveness of lifestyle interventions in adults with prediabetes. The overall intervention effect was synthesized using a ...
Generative AI adoption, regulatory scrutiny, DEI policy shifts, real-world evidence, and rare disease economics emerged as key themes across these most-read Applied Clinical Trials articles shaping ...
In the CAPItello-291 trial of capivasertib plus fulvestrant, 73% of patients had already received a CDK4/6 inhibitor. As compared with fulvestrant alone, the combination more than doubled the median ...
A new drug may slow progression of -- and even reverse -- symptoms of a rare form of amyotrophic lateral sclerosis, or ALS, a new study published Monday finds. The drug, tofersen, targets a very ...
For the 16th consecutive year, Norway was named the most democratic country in the world, with a score of 9.81. New Zealand and Sweden followed. Afghanistan has been the lowest-ranked country since ...
The FDA is raising the bar for approval of CAR T-cell therapies in oncology. Under plans outlined by the FDA’s biologics chief Vinay Prasad, M.D., the agency will require developers of many CAR-Ts to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback